In 2025, it is possible — and increasingly common — to treat cancer but lose a patient to a drug-resistant infection. This disturbing reality underscores the urgent, and often overlooked intersection of antimicrobial resistance (AMR) [...]
More news
Basel is the place to be this week, and believe us when we say it [...]
February 2024 – Xiretsa, Inc is the second selected venture to receive INCATEs Stage II [...]
Do you have an outstanding antimicrobial resistance (AMR) innovation that you would like to share [...]
After receiving over 40 applications and going through a rigorous decision process, the finalists for [...]
As December arrives and 2023 draws to a close, it's time for reflection. The statistics [...]
December 6th 2023 – INCATE (the INCubator for Antibacterial Therapies in Europe) and Kineticos AMR [...]
The INCATE Selection Committee selected the last 4 new ventures for Stage I support in [...]
On November 8th 2023 we organized INCATEs 3rd Entrepreneurs Club about ways to get funding [...]
